News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
An estimated 21 million American women experience BV
No new studies have been requested
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
BVX-0922 to target colorectal cancer under investigator-sponsored IND
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Subscribe To Our Newsletter & Stay Updated
